Lawsuit filed for Investors in shares of Pulse Biosciences, Inc. (NASDAQ: PLSE)

An investor, who purchased shares of Pulse Biosciences, Inc. (NASDAQ: PLSE), filed a lawsuit over alleged violations of Federal Securities Laws by Pulse Biosciences, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) have certain options and for certain investors are short and strict deadlines running. Deadline: April 18, 2022. NASDAQ: PLSE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Hayward, CA based Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
In October 2020, Pulse initiated its investigational device exemption ("IDE") study to evaluate the treatment of sebaceous hyperplasia lesions using the CellFX System.

On February 8, 2022, Pulse Biosciences, Inc announced that the U.S. Food and Drug Administration ("FDA") concluded there was insufficient clinical evidence to support the Company's 510(k) submission to expand the label for the CellFX System to treat sebaceous hyperplasia. Among other things, the FDA found "that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study."
Shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) declined from $13.36 per share on January 26, 2022 to as low as $6.34 per share on February 9, 2022.

The plaintiff claims that between January 12, 2021 and February 7, 2022, the Defendants failed to disclose to investors that the IDE study evaluating the use of the CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints, that, as a result, there was a substantial risk that the FDA would reject Pulse's 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Pulse Biosciences, Inc. (NASDAQ: PLSE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.